Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06728098 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Tolerability Evaluation of Akkermansia Muciniphila

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2025 (before its estimated December 25, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: May 25, 2025 to Dec 25, 2025v2 Show 6 more changesShow less
    • Start date: Feb 25, 2025 to Nov 25, 2025
    • Primary endpoint revised
    • Enrollment target: 90 to 108
    • Study completion date: Sep 25, 2025 to Mar 25, 2026
    • Eligibility criteria shortened, about 18 words
    • Study title shortened, about 2 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Akkermansia muciniphila Akk11 in healthy adult.
Trial Details
NCT Number NCT06728098
Lead Sponsor Wecare Probiotics Co., Ltd.
Conditions
(from sponsor)		 Healthy
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov